#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Veterans and first responders advocating for cannabis and psychedelic access at the federal level could reshape treatment options for PTSD, chronic pain, and mental health conditions that current VA pharmacotherapies inadequately address. Changes in state regulations allowing medical cannabis use within healthcare facilities and federal resentencing policies directly affect clinicians’ ability to discuss or recommend these treatments without legal liability and influence patient access to evidence-emerging therapies. Clinicians should monitor these policy developments as they may expand the clinical toolkit for conditions with high prevalence in veteran and first responder populations while creating new documentation and prescribing considerations.
Veterans and military service members are increasingly advocating for legislative changes to expand access to cannabis and psychedelics through the Veterans Affairs system and state-level healthcare facilities. Recent developments include momentum toward VA marijuana resentencing initiatives, regulatory changes in Oregon and Colorado permitting medical cannabis use within healthcare settings, Utah’s exploration of psychedelic-assisted therapies, and Maryland’s protections for firefighters using cannabis. These policy shifts reflect growing recognition that cannabis and psychedelics may address treatment-resistant conditions common in military populations, including PTSD, chronic pain, and depression, though federal scheduling conflicts continue to limit VA prescribing authority. For clinicians caring for veterans, these evolving state and federal regulations create an increasingly fragmented landscape where in-state legal access may not align with VA employment protections or benefit coverage. Clinicians should remain informed about their state’s specific regulations regarding cannabis and psychedelics in healthcare settings and be prepared to discuss these emerging therapeutic options with veteran patients while documenting the gap between state legalization and federal policy. Understanding these policy changes allows clinicians to better advocate for their patients’ interests and provide informed guidance about legal risks and practical access pathways.
“What we’re seeing with veterans advocating for cannabis and psychedelic access is fundamentally a demand that the VA catch up to clinical reality, and Congress needs to listen because these patients have already done the work of understanding what helps them with PTSD and treatment-resistant conditions that our conventional arsenal has failed to address.”
💚 As veterans and first responders increasingly advocate for expanded access to cannabis and psychedelics, clinicians should recognize that policy changes may outpace the evidence base and create practice complexities in their settings. While preliminary data suggest potential therapeutic roles for cannabis in chronic pain and PTSD and psilocybin in treatment-resistant depression, most evidence remains limited by small sample sizes, heterogeneous populations, and lack of long-term safety data in vulnerable populations like veterans with polytrauma or comorbid mental health conditions. Healthcare providers in states adopting these policies must grapple with the tension between patient autonomy and evolving institutional guidelines, as well as the challenge of counseling patients on risks and drug interactions when federal scheduling restricts research and clinical guidance. Clinicians should stay informed about their state and institutional policies, develop competency in screening for substance use disorders and contraindications, and maintain documentation of evidence-based discussions with patients, while
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: